Transgender Women
Research Study
Research Study
Join a University of Pennsylvania research study aimed at preventing HIV among transgender women by providing a daily medication that can be taken alongside hormone therapy.
Transgender Women
Research Study
Research Study
Join a University of Pennsylvania research study aimed at preventing HIV among transgender women by providing a daily medication that can be taken alongside hormone therapy.
Philadelphia, PA
Compensation
Provided
Provided
Not Diagnosed with HIV
Transgender Women
18 Years and Older
Fast Facts
About this research study:
Partner with University of Pennsylvania researchers to explore the benefits of receiving HIV prevention services and hormone therapy from the same medical provider.
HIV prevention is an important issue in the trans community. Transgender women are a priority for HIV prevention and treatment. Pre-exposure prophylaxis (PrEP) can dramatically reduce the risk of contracting HIV; however, many transgender women are concerned there may be drug interactions between gender affirming hormone therapy and PrEP.
Researchers at the University of Pennsylvania are studying the benefits of receiving PrEP and hormone therapy from the same medical provider. Join this compensated study that could lead to better prevention treatments for people in the transgender community.
Researchers at the University of Pennsylvania are studying the benefits of receiving PrEP and hormone therapy from the same medical provider. Join this compensated study that could lead to better prevention treatments for people in the transgender community.
Additional Information
Transgender women bear a disproportionate burden of HIV infection globally. Gender-affirming hormone therapy is an unmet need and community priority for TGW. An accepted and feasible intervention that delivers HIV prevention services with hormonal therapy could significantly impact the HIV epidemic among TGW.
The HPTN 091 study is testing the feasibility (will it work?), acceptability (do people like it?) and possible impact (does it make a difference?) of providing pre-exposure prophylaxis, also known as PrEP, co-located gender affirming services and Peer Health Navigation using Strengths-Based Case Management to improve PrEP uptake and adherence among transgender women (TGW).
You may qualify for this study if you meet the following criteria.
Key Criteria:
Key Criteria:
- Identifying as a transgender woman, or along a trans feminine spectrum and assigned male at birth
- At least 18 years of age
- Currently in good health
Participants will be assigned to one of two study groups:
1. Participants will receive PrEP, STI screening and treatment, co-located gender affirming services and Peer Health Navigation using Strengths-Based Case Management at the study site for 18 months.
OR
2. For the first 6 months, participants will receive PrEP, STI screening and treatment, but will be referred to receive gender affirming and health navigation services outside the study site. From 6-18 months, participants in this arm will receive PrEP, STI screening and treatment, co-located gender affirming services and Peer Health Navigation using Strengths-Based Case Management at the study site.
1. Participants will receive PrEP, STI screening and treatment, co-located gender affirming services and Peer Health Navigation using Strengths-Based Case Management at the study site for 18 months.
OR
2. For the first 6 months, participants will receive PrEP, STI screening and treatment, but will be referred to receive gender affirming and health navigation services outside the study site. From 6-18 months, participants in this arm will receive PrEP, STI screening and treatment, co-located gender affirming services and Peer Health Navigation using Strengths-Based Case Management at the study site.
You will be compensated for your participation.
There will be no charge to you for participating in this research program.